Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes.

• Published in: PLoS ONE
• Main Authors: Rania Hammami, Jihen Jdidi, Olfa Chakroun, Fadhila Issaoui, Nouha Ktata, Hanen Maamri, Mouna Baklouti, Amine Bahloul, Rania Gargouri, Abdennour Nasri, Sameh Msaad, Samy Kammoun, Samir Kammoun, Imen Ben Rejab, Selma Charfeddine, Leila Abid
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2022-01-01
• Online Access: https://doi.org/10.1371/journal.pone.0270195

<h4>Introduction</h4>There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life.<h4>Patients and methods</h4>This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients.<h4>Results</h4>We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%).<h4>Conclusions</h4>Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population.